GCMS-ID: a webserver for identifying compounds from gas chromatography mass spectrometry experiments.

GCMS-ID (Gas Chromatography Mass Spectrometry compound IDentifier) is a webserver designed to enable the identification of compounds from GC-MS experiments. GC-MS instruments produce both electron impact mass spectra (EI-MS) and retention index (RI) data for as few as one, to as many as hundreds of different compounds. Matching the measured EI-MS, RI or EI-MS + RI data to experimentally collected EI-MS and/or RI reference libraries allows facile compound identification. However, the number of available experimental RI and EI-MS reference spectra, especially for metabolomics or exposomics-related studies, is disappointingly small. Using machine learning to accurately predict the EI-MS spectra and/or RIs for millions of metabolomics and/or exposomics-relevant compounds could (partially) solve this spectral matching problem. This computational approach to compound identification is called in silico metabolomics. GCMS-ID brings this concept of in silico metabolomics closer to reality by intelligently integrating two of our previously published webservers: CFM-EI and RIpred. CFM-EI is an EI-MS spectral prediction webserver, and RIpred is a Kovats RI prediction webserver. We have found that GCMS-ID can accurately identify compounds from experimental RI, EI-MS or RI + EI-MS data through matching to its own large library of >1 million predicted RI/EI-MS values generated for metabolomics/exposomics-relevant compounds. GCMS-ID can also predict the RI or EI-MS spectrum from a user-submitted structure or annotate a user-submitted EI-MS spectrum. GCMS-ID is freely available at https://gcms-id.ca/.

DrugBank 6.0: the DrugBank Knowledgebase for 2024.

First released in 2006, DrugBank (https://go.drugbank.com) has grown to become the 'gold standard' knowledge resource for drug, drug-target and related pharmaceutical information. DrugBank is widely used across many diverse biomedical research and clinical applications, and averages more than 30 million views/year. Since its last update in 2018, we have been actively enhancing the quantity and quality of the drug data in this knowledgebase. In this latest release (DrugBank 6.0), the number of FDA approved drugs has grown from 2646 to 4563 (a 72% increase), the number of investigational drugs has grown from 3394 to 6231 (a 38% increase), the number of drug-drug interactions increased from 365 984 to 1 413 413 (a 300% increase), and the number of drug-food interactions expanded from 1195 to 2475 (a 200% increase). In addition to this notable expansion in database size, we have added thousands of new, colorful, richly annotated pathways depicting drug mechanisms and drug metabolism. Likewise, existing datasets have been significantly improved and expanded, by adding more information on drug indications, drug-drug interactions, drug-food interactions and many other relevant data types for 11 891 drugs. We have also added experimental and predicted MS/MS spectra, 1D/2D-NMR spectra, CCS (collision cross section), RT (retention time) and RI (retention index) data for 9464 of DrugBank's 11 710 small molecule drugs. These and other improvements should make DrugBank 6.0 even more useful to a much wider research audience ranging from medicinal chemists to metabolomics specialists to pharmacologists.

HMDB 5.0: the Human Metabolome Database for 2022.

The Human Metabolome Database or HMDB (https://hmdb.ca) has been providing comprehensive reference information about human metabolites and their associated biological, physiological and chemical properties since 2007. Over the past 15 years, the HMDB has grown and evolved significantly to meet the needs of the metabolomics community and respond to continuing changes in internet and computing technology. This year's update, HMDB 5.0, brings a number of important improvements and upgrades to the database. These should make the HMDB more useful and more appealing to a larger cross-section of users. In particular, these improvements include: (i) a significant increase in the number of metabolite entries (from 114 100 to 217 920 compounds); (ii) enhancements to the quality and depth of metabolite descriptions; (iii) the addition of new structure, spectral and pathway visualization tools; (iv) the inclusion of many new and much more accurately predicted spectral data sets, including predicted NMR spectra, more accurately predicted MS spectra, predicted retention indices and predicted collision cross section data and (v) enhancements to the HMDB's search functions to facilitate better compound identification. Many other minor improvements and updates to the content, the interface, and general performance of the HMDB website have also been made. Overall, we believe these upgrades and updates should greatly enhance the HMDB's ease of use and its potential applications not only in human metabolomics but also in exposomics, lipidomics, nutritional science, biochemistry and clinical chemistry.

Draft genome sequencing data of multidrug-resistant Staphylococcus haemolyticus from Bangladeshi hospitals.

Here, we report the draft genome sequence data of two multidrug-resistant (MDR) Staphylococcus haemolyticus strains, SAC2 and SAC7, isolated from clinical samples from Dhaka, Bangladesh. The sequence raw read files were generated using Ion Torrent Sequencing Technology using the genomic DNA from the pure culture of the strains. These two Bangladeshi S. haemolyticus strains had an average genome size of 2.49 million base pairs with a GC content of 32.6 % and an average of 1783 coding sequences. We conducted genomic studies using bioinformatics tools focusing on resistance genes, virulence factors, and toxin-antitoxin systems. A phylogenomic study with S. haemolyticus strains isolated worldwide revealed that these two Bangladeshi strains are in different nodes but clustered together. The data can be used as a starting point for understanding the genomic content, epidemiology, and evolution of S. haemolyticus in Bangladesh. The genome sequence data of SAC2 and SAC7 strains have been deposited in the NCBI database under BioSample accession numbers SAMN35731443 and SAMN35731649, respectively.

Introducing 'identification probability' for automated and transferable assessment of metabolite identification confidence in metabolomics and related studies.

Methods for assessing compound identification confidence in metabolomics and related studies have been debated and actively researched for the past two decades. The earliest effort in 2007 focused primarily on mass spectrometry and nuclear magnetic resonance spectroscopy and resulted in four recommended levels of metabolite identification confidence - the Metabolite Standards Initiative (MSI) Levels. In 2014, the original MSI Levels were expanded to five levels (including two sublevels) to facilitate communication of compound identification confidence in high resolution mass spectrometry studies. Further refinement in identification levels have occurred, for example to accommodate use of ion mobility spectrometry in metabolomics workflows, and alternate approaches to communicate compound identification confidence also have been developed based on identification points schema. However, neither qualitative levels of identification confidence nor quantitative scoring systems address the degree of ambiguity in compound identifications in context of the chemical space being considered, are easily automated, or are transferable between analytical platforms. In this perspective, we propose that the metabolomics and related communities consider identification probability as an approach for automated and transferable assessment of compound identification and ambiguity in metabolomics and related studies. Identification probability is defined simply as 1/N, where N is the number of compounds in a reference library or chemical space that match to an experimentally measured molecule within user-defined measurement precision(s), for example mass measurement or retention time accuracy, etc. We demonstrate the utility of identification probability in an in silico analysis of multi-property reference libraries constructed from the Human Metabolome Database and computational property predictions, provide guidance to the community in transparent implementation of the concept, and invite the community to further evaluate this concept in parallel with their current preferred methods for assessing metabolite identification confidence.

Accurate prediction of isothermal gas chromatographic Kováts retention indices.

We describe a freely available web server called Retention Index Predictor (RIpred) (https://ripred.ca) that rapidly and accurately predicts Gas Chromatographic Kováts Retention Indices (RI) using SMILES strings as chemical structure input. RIpred performs RI prediction for three different stationary phases (semi-standard non-polar (SSNP), standard non-polar (SNP), and standard polar (SP)) for both derivatized (trimethylsilyl (TMS) and tert­butyldimethylsilyl (TBDMS) derivatized) and underivatized (base compound) forms of GC-amenable structures. RIpred was developed to address the need for freely available, fast, highly accurate RI predictions for a wide range of derivatized and underivatized chemicals for all common GC stationary phases. RIpred was trained using a Graph Neural Network (GNN) that used compound structures, their extracted features (mostly atom-level features) and the GC-RI data from the National Institute of Standards and Technology databases (NIST 17 and NIST 20). We curated this NIST 17 and NIST 20 GC-RI data, which is available for all three stationary phases, to create appropriate inputs (molecular graphs in this case) needed to enhance our model performance. The performance of different RIpred predictive models was evaluated using 10-fold cross validation (CV). The best performing RIpred models were identified and when tested on hold-out test sets from all stationary phases, achieved a Mean Absolute Error (MAE) of <73 RI units (SSNP: 16.5-29.5, SNP: 38.5-45.9, SP: 46.52-72.53). The Mean Absolute Percentage Error (MAPE) of these models were typically within 3% (SSNP: 0.78-1.62%, SNP: 1.87-2.88%, SP: 2.34-4.05%). When compared to the best performing model by Qu et al., 2021, RIpred performed similarly (MAE of 16.57 RI units [RIpred] vs. 16.84 RI units [Qu et al., 2021 predictor] for derivatized compounds). RIpred also includes ∼5 million predicted RI values for all GC-amenable compounds (∼57,000) in the Human Metabolome Database HMDB 5.0 (Wishart et al., 2022).

A longitudinal dataset of incidence and intervention policy impacts regarding the COVID-19 pandemic in Canadian provinces.

One year after identifying the first case of the 2019 coronavirus disease (COVID-19) in Canada, federal and provincial governments are still struggling to manage the pandemic. Provincial governments across Canada have experimented with widely varying policies in order to limit the burden of COVID-19. However, to date, the effectiveness of these policies has been difficult to ascertain. This is partly due to the lack of a publicly available, high-quality dataset on COVID-19 interventions and outcomes for Canada. The present paper provides a dataset containing important, Canadian-specific data that is known to affect COVID-19 outcomes, including sociodemographic, climatic, mobility and health system related information for all 10 Canadian provinces and their health regions. This dataset also includes longitudinal data on the daily number of COVID-19 cases, deaths, and the constantly changing intervention policies that have been implemented by each province in an attempt to control the pandemic.